Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#13 How Long Before Antidepressants Work: Happy News?


CLINICAL QUESTION
QUESTION CLINIQUE
How quickly do the effects of antidepressants become clinically evident?


BOTTOM LINE
RÉSULTAT FINAL
Antidepressants begin to work as early as one week and continue to provide incremental benefits on depressive symptoms weekly for at least six weeks.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
A large meta-analysis addresses this question:
  • A meta-analysis1 of 28 trials (5872 depressed patients) looked at response to SSRI medications, compared to placebo at a series of time intervals up to six weeks:
    • At week one, the average patient gets about 1/3 of the six-week absolute benefit.
    • The incremental benefit is greatest at week one and the magnitude of the additional benefits gradually declines week by week.
    • To get a ≥50% reduction in the Hamilton Rating Scale for Depression (HRSD or HAM-D)
      • At one week, Numbers Needed to Treat (NNT)=25.
      • At six weeks, NNT=9.
Context:
  • The results of the study above confirm those of another meta-analysis,2 which also found that antidepressants result in statistically significant improvement in clinically important outcomes within the first week.
  • Since previous trials involved fewer patients, they were underpowered to adequately assess early response; this led to the misconception that SSRIs always take four to six weeks to work.
  • Note: NNT describes the benefit of SSRI over placebo, but the placebo response in depression is high. In practice, we will see more than one in every 25 or nine patients improve at weeks one and six, respectively.


Latest Tools for Practice
Derniers outils pour la pratique

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Ron Shute MD CCFP

1. Taylor JT, Freemantle N, Geddes JR, et al. Arch Gen Psychiatry. 2006; 63:1217-23.

2. Papakostas GI, Perlis RH, Scalia MJ, et al. J Clin Psychopharmacol. 2006; 26:56-60.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 13/07/2016

By: Ricky D Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: No new evidence; Bottom Line: No change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks